国: アイルランド
言語: 英語
ソース: HPRA (Health Products Regulatory Authority)
CALCIUM ACETATE MAGNESIUM CARBONATE HEAVY
Fresenius Medical Care Nephrologica Deutschland GmbH
CALCIUM ACETATE MAGNESIUM CARBONATE HEAVY
435 / 235 Milligram
Film Coated Tablet
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT OsvaRen 435 mg / 235 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains: Calcium acetate, 435.00 mg equivalent to 110 mg calcium and Magnesium carbonate, heavy 235.00 mg equivalent to 60 mg magnesium. Excipients: Each film-coated tablet contains max. 5.6 mg sodium and 50.00 mg sucrose. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White to yellowish, oblong film-coated tablet with a single score line. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of hyperphosphatemia associated with chronic renal insufficiency in patients undergoing dialysis (haemodialysis, peritoneal dialysis). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults_ 3 to 10 film-coated tablets per day, depending on the serum phosphate level. The daily dose should be subdivided according to the number of meals taken over the day (usually three a day). The recommended starting dose is three tablets daily. If necessary, the dosage may be raised to maximally 12 film-coated tablets per day. To achieve the maximum phosphate binding effect, OsvaRen should be taken only together with the meal and should not be crushed or chewed. For easy swallowing, the tablets should be taken together with some liquid. In case the tablets are too large to be swallowed by the patient, the tablets should be broken along the score line immediately before swallowing in order to avoid the development of taste of acetic acid. Because the rate and/or extent of absorption of other oral medicinal products may vary when used concurrently with OsvaRen no other oral 完全なドキュメントを読む